Study of DF6215 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
DF6215-001 is a study of a modified human cytokine (interleukin-2; IL-2) that retains the
ability to bind to a certain part of the IL-2 receptor on a subset of white blood cells
(lymphocytes), which can help recognize and kill tumor cells. The study will occur in two
phases. The first phase will be a dose escalation phase, enrolling patients with various
types of solid tumors. The second phase, Phase 1b, will include a dose expansion using the
best dose selected from the first phase of the study. A cohort will be opened with eligible
patients having a select solid tumor.